US20060106421A1 - Expansible neck bridge - Google Patents
Expansible neck bridge Download PDFInfo
- Publication number
- US20060106421A1 US20060106421A1 US10/990,163 US99016304A US2006106421A1 US 20060106421 A1 US20060106421 A1 US 20060106421A1 US 99016304 A US99016304 A US 99016304A US 2006106421 A1 US2006106421 A1 US 2006106421A1
- Authority
- US
- United States
- Prior art keywords
- aneurysm
- base section
- struts
- strut
- swellable material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010002329 Aneurysm Diseases 0.000 claims abstract description 86
- 239000000463 material Substances 0.000 claims abstract description 46
- 239000000017 hydrogel Substances 0.000 claims description 23
- 239000003550 marker Substances 0.000 claims description 18
- -1 poly(sodium-4-styrenesulfonate) Polymers 0.000 claims description 18
- 229910045601 alloy Inorganic materials 0.000 claims description 10
- 239000000956 alloy Substances 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 229920000431 shape-memory polymer Polymers 0.000 claims description 6
- 239000010935 stainless steel Substances 0.000 claims description 6
- 229910001220 stainless steel Inorganic materials 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 210000002744 extracellular matrix Anatomy 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- 229920001464 poly(sodium 4-styrenesulfonate) Polymers 0.000 claims 2
- 239000004584 polyacrylic acid Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 6
- 230000003073 embolic effect Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000002788 crimping Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010072064 Exposure to body fluid Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 229920006187 aquazol Polymers 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 108700005457 microfibrillar Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920001042 poly(δ-valerolactone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/1219—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
- A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12177—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure comprising additional materials, e.g. thrombogenic, having filaments, having fibers or being coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00867—Material properties shape memory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
Definitions
- the present invention deals with medical devices. Potentially, the devices could be used in a variety of body spaces, but the present description will be in the context of treatments for vascular aneurysms. Accordingly, one aspect of the present invention deals with a medical device for bridging, and at least partially obstructing, the neck portion of a vascular aneurysm.
- Vascular aneurysms are typically formed due to a weakening in the walls of an artery. Often aneurysms are the site of internal bleeding and strokes. Left untreated aneurysms could rupture, causing potentially fatal consequences to the patient.
- Different medical devices have been developed for treating vascular aneurysms. Treatments commonly known as “artificial vaso-occlusion” treatments are known to be useful in treating aneurysms by filling associated undesirable vascular spaces. The space then becomes essentially closed off from the vessel and normal blood flow is restored.
- a variety of different vaso-occlusive devices are known to be effective for the treatment of aneurysms. The devices are introduced typically via a catheter to the site within the vasculature that is to be closed. That site may be within an aneurysm stemming from a blood vessel or within the blood vessel lumen itself.
- injectable fluids such as microfibrillar collagen, various polymeric foams and beads have been used.
- Certain injectable fluid devices can be introduced through a catheter and are capable of forming a solid space-filling mass in a target location.
- Polymeric resins, particularly cyanoacrylate resins, have been used as injectable vaso-occlusive materials. Both the injectable gel and resin materials are typically mixed with a radio-opaque material to allow accurate setting of the resulted materials.
- vaso-occlusive devices To further increase occlusive properties and thrombogenicity, a variety of vaso-occlusive devices have been treated with a variety of substances.
- U.S. Pat. No. 4,994,069 to Ritchart et al., describes a vaso-occlusive coil that assumes a linear helical configuration when stretched and a folded, convoluted configuration when relaxed. The stretched condition is used in placing the coil at the desired site (via passage through the catheter) and the coil assumes a relaxed configuration-which is better suited to occlude the vessel-once the device is so-placed.
- Ritchart et al. describes a variety of shapes.
- the secondary shapes of the disclosed coils include “flower” shapes and double vortices.
- the coils may be coated with agarose, collagen, or sugar.
- Vaso-occlusion coils are generally constructed of a wire, usually made of a metal or metal alloy, which is wound into a helix. Most commonly, these coils are introduced in a stretched linear form through a catheter to the selected target site, such as a particular aneurysm. The vaso-occlusion coils typically assume an irregular shape upon discharge of the device from the distal end of the catheter. The coils may undertake any of a number of random configurations used to fill an aneurysm. In some instances, vaso-occlusion coils are adapted to assume a predetermined secondary shape designed to enhance the ability to fill undesirable vascular spaces.
- vaso-occlusion coils and braids are known. Tungsten, platinum, and gold threads or wires are said to be preferred.
- Vaso-occlusion coils have a variety of benefits including that they are relatively permanent, they may be easily imaged radiographically, they may be located at a well defined vessel site, and they can be retrieved.
- vaso-occlusion coils In some instances, particularized features of coil designs, such as specialized mechanisms for delivering vaso-occlusion coils through delivery catheters and implanting them in a desired occlusion site, have been described. Examples of categories of vaso-occlusion coils having specialized delivery mechanisms include pushable coils, mechanically detachable coils, and electrolytically detachable coils.
- Pushable coils are commonly provided in a cartridge and are pushed or plunged from an engaged delivery catheter into an aneurysm.
- a pusher wire advances the pushable coils through and out of the delivery catheter into the site for occlusion.
- Mechanically detachable vaso-occlusive devices are typically integrated with a pusher wire and are mechanically detached from the distal end of that pusher wire after exiting a delivery catheter.
- U.S. Pat. No. 5,234,437 shows a method of unscrewing a helically wound coil from a pusher having an interlocking surface.
- U.S. Pat. No. 5,250,071, to Palermo shows an embolic coil assembly using interlocking clasps that are mounted both on the pusher and on the embolic coil.
- U.S. Pat. No. 5,261,195 shows a pusher-vaso-occlusive coil assembly having an affixed, proximately extending wire carrying a ball on its proximal end and a pusher having a similar end.
- U.S. Pat. No. 5,312,415 to Palermo
- U.S. Pat. No. 5,350,297 to Palermo et al., shows a pusher having a throat at its distal end and a pusher through its axis. The pusher sheath will hold onto the end of an embolic coil and will then be released upon pushing the axially placed pusher wire against the member found on the proximal end of the vaso-occlusive coil.
- the vaso-occlusive portion of the assembly is attached to a pusher wire via a small electrolytically severable joint.
- the electrolytically severable joint is severed by the placement of an appropriate voltage on the core wire.
- the joint erodes in preference either to the vaso-occlusive device itself or to the pusher wire.
- parts of the wire that are not intended to erode are often simply insulated to prevent such an electrolytic response caused by the imposition of the electrical current.
- vaso-occlusive devices include specialized mechanical features and/or shapes.
- Various shaped coils have been described.
- U.S. Pat. No. 5,624,461, to Mariant describes a three-dimensional in-filling vaso-occlusive coil.
- U.S. Pat. No. 5,639,277, to Mariant et al. describes embolic coils having twisted helical shapes and
- U.S. Pat. No. 5,649,949, to Wallace et al. describes variable cross-section conical vaso-occlusive coils. A random shape is described, as well.
- U.S. Pat. No. 5,537,338 describes a multi-element intravascular occlusion device in which shaped coils may be employed.
- Spherical shaped occlusive devices are described in U.S. Pat. No. 5,645,558 to Horton. Horton describes how one or more strands can be wound to form a substantially hollow spherical or ovoid shape when deployed in a vessel.
- U.S. Pat. Nos. 5,690,666 and 5,718,711, by Berenstein et al. show a very flexible vaso-occlusive coil having little or no shape after introduction into the vascular space.
- vaso-occlusive devices in particular, vaso-occlusion coils, lacking substantial secondary shape strength may be difficult to maintain in position within an aneurysm no matter how skillfully they are placed.
- Vaso-occlusive devices are typically placed in an aneurysm in the following fashion.
- a micro-catheter is initially steered into or adjacent the entrance of an aneurysm, typically aided by the use of a steerable guide wire.
- the guide wire is then withdrawn from the micro-catheter and replaced by the vaso-occlusive device or a separate catheter is delivered containing the vaso-occlusive device.
- the vaso-occlusive device is advanced through and out of a micro-catheter, desirably being completely delivered into the aneurysm.
- the device or a portion of the device might migrate out of the aneurysm entrance zone and into the feeding vessel.
- the presence of the device in the feeding vessel may cause the undesirable response of an occlusion in the feeding vessel.
- there is a quantifiable risk that blood flow in the feeding vessel and the aneurysm may induce movement of the device further out of the aneurysm, resulting in a more developed embolus in the patent vessel.
- a stent containing an outer layer of hydrogel has been presented in the art.
- the stent can be placed in the parent vessel near the site of the aneurysm and allowed to hydrate. While potentially closing off the aneurysm neck this device unfortunately also unnecessarily seals off other parts of the vessel it contacts. This presents risks of creating stenosis or introducing emboli within the vessel.
- a device to bridge and seal the neck of the aneurysm thereby retaining the vaso-occlusive device within the aneurysm sac and allowing normal blood flow through the vessel.
- Another disclosed invention involves the use of hydrogel embolizing elements disposed concentrically on a filament and deployed within the aneurysm sac. Upon hydration the vaso-occlusive device expands to fill the space within the sac. Potentially the expansion of the device could extend out from the aneurysm and disrupt normal blood flow or create emboli. A need exists for a device to bridge the neck of the aneurysm thereby retaining the vaso-occlusive device within the aneurysm sac.
- aneurysms present particularly acute medical risk due to the dangers associated with an inherently thin vascular wall.
- the utilization of vaso-occlusive devices to occlude an aneurysm without occluding the adjacent vasculature pose a special challenge. It is especially difficult when addressing wide neck aneurysms due to morphology, shape or herniation. There exists a need for a device to bridge and obstruct the wide necked aneurysms from within the aneurysm. None of the vaso-occlusive devices described above solve this problem.
- the medical device could be implantable and includes an apparatus having a base and at least one strut or lateral protrusion fixedly attached to the base.
- the apparatus including the base and strut(s), is of a size and overall flexibility to lodge inside the aneurysm at the neck portion.
- a swellable material such as hydrogel, is selectively applied to the strut(s) providing a therapeutic effect on the vascular aneurysm.
- FIG. 1 is a side view of the retainer assembly.
- FIG. 2 is a side view of the retainer assembly with attached marker coils.
- FIG. 3 is a side view of an aneurysm emanating from the wall of a blood vessel.
- FIG. 4 is a partial sectioned view of the retainer assembly being inserted within the aneurysm sac.
- FIG. 5 is a side view of the retainer assembly lodged against the side wall of the aneurysm showing a coil having a swellable material attached in the vicinity of the aneurysm neck.
- FIG. 6 is a partial sectioned view of the retainer assembly as the vaso-occlusive catheter delivery device is positioned.
- FIG. 7 is a side view of the retainer assembly.
- FIG. 8 is a side view of the retainer assembly and illustrates the procedural elements associated with using the retainer assembly.
- FIG. 9 is a partial sectioned view of the aneurysm with both the retainer and vaso-occlusive devices inside the aneurysm.
- FIG. 10 is a perspective view of the aneurysm closed off.
- This invention involves a device and procedure for solving the problem of material flow into and out of aneurysms.
- a retainer assembly is placed at the mouth of the aneurysm sac, forming a barrier for blood flow into the sac or migration of other devices, such as vaso-occlusive implants, out of the sac.
- Vaso-occlusive implants may be placed inside the sac for filling the unwanted space.
- the retainer assembly includes a swellable material placed on the spanning support framework to further close off the the aneurysm sac. The swellable material absorbs fluid upon contact with blood and expands in volume. The retainer assembly with the expanded swellable material seals off the neck of the aneurysm, preventing vaso-occlusive devices from migrating into the parent vessel.
- FIG. 1 illustrates a retainer assembly 10 with a base 20 and at least one strut 30 extending from the base 20 laterally.
- the base 20 is preferably constructed of a coil 22 with a proximal and distal end and a lumen throughout.
- the coil 22 is preferably made from stainless steel, or other biocompatible material including shape memory polymers, and is approximately 0.017 inches in diameter and approximately 1.0 millimeter in length.
- the base 20 is centrally located when a plurality of struts 30 extend outwardly in different directions from the base 20 , as shown in FIG. 1 .
- the base 20 is connected to a delivery device at the proximal end of the coil 22 .
- Retainer assembly 10 includes lateral struts 30 that could either be round or flat wire, or any other construction that forms a scaffolding or bridge across the neck of the aneurysm.
- the diameter of the wires or ribbons making up the strut elements 30 is preferably smaller than about 0.010 inches.
- the struts 30 may be produced from a number of materials such as metals, alloys, polymers, or other biocompatible medical device materials. Due to their desired expansion properties, superelastic alloys are commonly and desirably utilized in the strut 30 construction.
- Superelastic alloys are well known in the art. Nitinol, which comprises the elements nickel and titanium, is one of the more well known super-elastic alloys. It is readily commercially available and undergoes the austenitic-martensitic-austenitic transformation in a variety of temperatures between ⁇ 20C and +30C.
- the struts 30 of the current invention be made from superelastic alloys
- other metals include a number of stainless steel materials and other highly elastic, if not superelastic alloys.
- the struts 30 be formed from polymeric materials. Such materials as polyethylene, polypropylene, various nylons, shape memory polymers, or polytetrafluoroethylene could be chosen along with a variety of other suitable polymeric materials which are biocompatible and fit the criteria necessary for this invention.
- the retainer assembly 10 has an overall shape which approximates that of the aneurysm neck in which it is placed. Specifically, the retainer assembly 10 has a number of struts 30 which extend from the base 20 , loop around and rejoin themselves to the base 20 forming a spanning support frame. The lateral struts 30 are connected to the distal end of the base by methods known to those skilled in the art, such as welding, crimping, adhesive bonding, or fusing. While the preferred embodiment, as shown in FIG. 1 , includes struts 30 that loop around and connect to the base 20 , other types of lateral protrusions should be considered within the scope of the present invention. FIG. 1 illustratively includes three struts 30 , more or fewer could be utilized and are within the scope of the invention.
- the retainer assembly 10 including three struts 30 creates a spanning “flower” shape.
- the illustrated struts 30 are generally shown to be approximately the same size and shape with respect to each other, this is not necessary. It is within the scope of this invention that the retainer assembly 10 be irregular in shape to fit within an irregularly shaped aneurysm.
- the length of the struts 30 is generally appropriate to form a spanning element which contacts points along the inside of the aneurismal wall (further described in FIG. 5 ) and connects to the base 20 . While a certain minimal contact with the aneurysm wall is necessary to support the bridging struts 30 it is also possible for the retainer device to include struts 30 which extend further along the inside wall of the aneurismal sac.
- the struts 30 further contain an expansible material 50 , such as hydrogel, selectively attached for further occluding the aneurysm neck.
- the material 50 is disposed on the struts 30 in locations, as shown in FIG. 1 , which span and provide framework across the opening of the aneurysm sac.
- the hydrogel 50 swells and effectively seals off the aneurysm by reducing the effective open area of the aneurysm neck.
- the absorbent material 50 is preferably formed of a polymeric colloidal system which is biocompatible. It may be a hydrogel or other such material with properties allowing it to swell and stabilize upon exposure to body fluids.
- hydrogels include gels formed from homopolymers, copolymers, and/or network polymers containing: polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylates, polymethacrylates, polyacrylamides, polyethyloxazoline, polysaccharides, mucopolysaccharides, polyaminoacids, carboxy alkyl celluloses, partially oxidized cellulose, hyaluronic acid, dextran, heparin sulfate, chondroitin sulfate, heparin, agar, starch, alginate, fibronectin, gelatin, collagen, fibrin, pectins, albumin, ovalbumin, polyesters of .alpha.-hydroxy
- the gel may further comprises a chemical cross-linking agent having two or more reactive groups in order to form chemical bridges between two or more polymeric molecules
- cross-linking agents include diacrylates, oligoacrylates, dimethacrylates, oligomethacrylates, divinyl ethers, certain cations, and combinations thereof.
- the swellable material 50 can preferably be coated on the struts 30 or array members of the retainer assembly 10 at the neck bridging locations.
- the hydrogel 50 may be fixed to the struts 30 by a suitable biocompatible adhesive or other mechanical or chemical adhesion processes known in the art. These include spray or dip coating, chemical or plasma deposition or any other form of simple mechanical attachment or restriction.
- the preferred method will allow the hydrogel 50 material to remain permanently attached to the struts 30 before, during and after delivery and hydration.
- the bonding method will allow expansion of the assembly 10 to its secondary shape without detrimental effects to the outer layer of hydrogel 50 .
- the hydrogel 50 may be of a type that dissolves over time and may include growth factors or other biologic materials such as collagen or fibrin to facilitate thrombosis and cell infiltration.
- Bioactive materials may be incorporated into the hydrogel 50 , including cytokines, growth factors, extracellular matrix molecules, proteins, enzymes, enzyme inhibitors, receptors, cells, polynucleic acids, lipid-based molecules, polysaccharides, drugs and fragments or combinations of these materials.
- the hydrogel 50 may also incorporate radiopaque materials.
- the distribution and arrangement of the hydrogel matrix 50 on the array struts 30 covering the aneurysm neck may be controllable and shaped to allow certain sized objects, such as blood, to escape while trapping embolus or PVA particles if required.
- the hydrogel 50 can also be used to effectively close off the neck area.
- a braid like structure or other pre-biased geometry, formed of hydrogel 50 can be disposed on the array struts 30 and configured to expand outward from the struts to develop a sheet, or flat panel, as opposed to possibly expanding into the parent vessel and potentially occluding blood flow. Preferential expansion may also be accomplished by the use of coatings or elements within the hydrogel 50 which restrict expansion. Changes in pH or temperature, or other external activation methods, may be used to initiate the selectively expandable hydrogel 50 in a certain direction or to a certain volume.
- Marker coils 60 are constructed of radio-opaque material (ie. platinum) and assist in the guidance of the retainer assembly through a tubular delivery device and through a vascular system using radiography or fluoroscopy.
- the marker coils 60 facilitate positioning of the bridge subassembly 10 within the aneurysm.
- the marker coils 60 may be placed at the site of overlapping struts 30 , the base of the retainer assembly 20 or any location along the strut 30 protrusions that assists in the placement of the assembly within the aneurysm.
- One embodiment, illustrated in FIG. 2 includes a base 20 with a marker 60 attached to the coil 22 .
- the marker 60 includes an inner 62 and outer marker coil 64 .
- the ends of the struts 30 are illustratively fixedly secured between the inner marker coil 62 and outer marker coil 64 .
- the struts or lateral protrusions 30 may include marker coils 60 , shown in FIG. 2 attached at the location where the struts 30 overlap.
- the marker coils 60 may be added to the various elements of the device by methods known within the art such as plating, crimping or wrapping the element in a radio-opaque wire or ribbon.
- the proximal portion of the base 20 is detachably connected to a severable joint 80 within a catheter 70 .
- the severing action of the joint 80 enables the retainer assembly 10 to remain in a portion of the aneurysm 90 after the catheter 70 has been removed from the vasculature 92 .
- the severable joint 80 is an electrolytic severable joint 80 .
- FIG. 3 illustrates a cross sectioned view of an aneurysm 90 emanating from the wall 92 of a blood vessel.
- a catheter 70 is shown in FIG. 4 delivering a retainer assembly 10 .
- the retainer assembly 10 is designed to fit inside a catheter 70 for delivery through the vasculature 92 .
- the retainer assembly 10 is positioned at the neck 94 , or opening of the aneurysm, as shown in FIG. 5 .
- the retainer assembly 10 takes its secondary, or expanded, shape as it is pushed out of the distal end of the catheter 70 .
- the catheter 70 contains a radio-opaque band or coil 60 at its distal end.
- radio-opaque band 60 assists in the guidance of catheter 70 through the vasculature 92 using fluoroscopy or radiology.
- the distal end of catheter 70 can be guided through the neck portion of the aneurysm 94 .
- the retainer assembly 10 can be pushed out of the distal end of the catheter 70 thus providing a device for aneurismal occlusion, as seen in FIG. 5 .
- the base 20 In order for the retainer assembly 10 to be implanted in the aneurysm 90 , the base 20 must be detachably connected to a catheter 70 , see FIG. 5 .
- one method for detachment of the base 20 from the catheter 70 is by activation of an electrolytically severable joint 80 .
- the severable joint 80 connects the distal end of a core wire 75 , as shown in FIG. 4 , to the base 20 of the retainer assembly 10 .
- the severable joint 80 and the action of releasing the retainer assembly 10 has been described in detail in U.S. Pat. No. 6,569,179, incorporated herein for reference. There are, of course, other means for detaching the retainer assembly 10 which should be considered within the scope of the invention.
- Retainer assembly 10 is further depicted in FIG. 5 showing placement against the side wall 96 .
- Lateral struts 30 in combination with base section 20 make up the bridge retainer assembly 10 .
- lateral struts or protrusions 30 are illustratively wire loops, other types of struts 30 should be considered within the scope of the present invention.
- the struts 30 further contain an absorbent material 50 , such as hydrogel, selectively attached for further occluding the aneurysm neck 94 . Upon hydration with time, the hydrogel 50 swells and effectively seals off the aneurysm neck 94 .
- FIGS. 6 and 7 show vaso-occlusive devices 77 , such as vaso-occlusion coils, pushed through a catheter 70 and retainer assembly 10 inside the aneurysm 90 . Coiling can be performed during expansion of the hydrogel 50 to stabilize the device within the aneurysm 90 .
- FIGS. 8, 9 and 10 depict the aneurysm 90 filling with vaso-occlusive devices 77 while being retained by the bridge retainer assembly 10 .
Abstract
Description
- The present invention deals with medical devices. Potentially, the devices could be used in a variety of body spaces, but the present description will be in the context of treatments for vascular aneurysms. Accordingly, one aspect of the present invention deals with a medical device for bridging, and at least partially obstructing, the neck portion of a vascular aneurysm.
- Vascular aneurysms are typically formed due to a weakening in the walls of an artery. Often aneurysms are the site of internal bleeding and strokes. Left untreated aneurysms could rupture, causing potentially fatal consequences to the patient. Different medical devices have been developed for treating vascular aneurysms. Treatments commonly known as “artificial vaso-occlusion” treatments are known to be useful in treating aneurysms by filling associated undesirable vascular spaces. The space then becomes essentially closed off from the vessel and normal blood flow is restored. A variety of different vaso-occlusive devices are known to be effective for the treatment of aneurysms. The devices are introduced typically via a catheter to the site within the vasculature that is to be closed. That site may be within an aneurysm stemming from a blood vessel or within the blood vessel lumen itself.
- There are a variety of materials and devices that have been used to create vaso-occlusions or emboli in the vasculature of the human body. For instance, injectable fluids such as microfibrillar collagen, various polymeric foams and beads have been used. Certain injectable fluid devices can be introduced through a catheter and are capable of forming a solid space-filling mass in a target location. Polymeric resins, particularly cyanoacrylate resins, have been used as injectable vaso-occlusive materials. Both the injectable gel and resin materials are typically mixed with a radio-opaque material to allow accurate setting of the resulted materials. Although some of these agents provide for excellent short-term occlusion, many are thought to allow vessel recanalization due to absorption of the agents into the blood. In addition, there are significant risks involved in use of cyanocrylates, and similar materials, due to the potential for misplacement. Such misplacement can create emboli in undesired areas. Generally, injectable fluid occlusion devices are somewhat difficult, if not impossible, to retrieve once they are improperly placed.
- To further increase occlusive properties and thrombogenicity, a variety of vaso-occlusive devices have been treated with a variety of substances. For instance, U.S. Pat. No. 4,994,069, to Ritchart et al., describes a vaso-occlusive coil that assumes a linear helical configuration when stretched and a folded, convoluted configuration when relaxed. The stretched condition is used in placing the coil at the desired site (via passage through the catheter) and the coil assumes a relaxed configuration-which is better suited to occlude the vessel-once the device is so-placed. Ritchart et al. describes a variety of shapes. The secondary shapes of the disclosed coils include “flower” shapes and double vortices. The coils may be coated with agarose, collagen, or sugar.
- As has been alluded to above, advancements in the artificial occlusion of aneurysms have occurred due to the delivery and implantation of metal coils as vaso-occlusive devices.
- Vaso-occlusion coils are generally constructed of a wire, usually made of a metal or metal alloy, which is wound into a helix. Most commonly, these coils are introduced in a stretched linear form through a catheter to the selected target site, such as a particular aneurysm. The vaso-occlusion coils typically assume an irregular shape upon discharge of the device from the distal end of the catheter. The coils may undertake any of a number of random configurations used to fill an aneurysm. In some instances, vaso-occlusion coils are adapted to assume a predetermined secondary shape designed to enhance the ability to fill undesirable vascular spaces.
- A variety of vaso-occlusion coils and braids are known. Tungsten, platinum, and gold threads or wires are said to be preferred. Vaso-occlusion coils have a variety of benefits including that they are relatively permanent, they may be easily imaged radiographically, they may be located at a well defined vessel site, and they can be retrieved.
- In some instances, particularized features of coil designs, such as specialized mechanisms for delivering vaso-occlusion coils through delivery catheters and implanting them in a desired occlusion site, have been described. Examples of categories of vaso-occlusion coils having specialized delivery mechanisms include pushable coils, mechanically detachable coils, and electrolytically detachable coils.
- Pushable coils are commonly provided in a cartridge and are pushed or plunged from an engaged delivery catheter into an aneurysm. A pusher wire advances the pushable coils through and out of the delivery catheter into the site for occlusion.
- Mechanically detachable vaso-occlusive devices are typically integrated with a pusher wire and are mechanically detached from the distal end of that pusher wire after exiting a delivery catheter.
- A variety of mechanically detachable devices are also known. For instance, U.S. Pat. No. 5,234,437, to Sepetka, shows a method of unscrewing a helically wound coil from a pusher having an interlocking surface. U.S. Pat. No. 5,250,071, to Palermo, shows an embolic coil assembly using interlocking clasps that are mounted both on the pusher and on the embolic coil. U.S. Pat. No. 5,261,195, to Twyford et al., shows a pusher-vaso-occlusive coil assembly having an affixed, proximately extending wire carrying a ball on its proximal end and a pusher having a similar end. The two ends are interlocked and disengaged when expelled from the distal tip of the catheter. U.S. Pat. No. 5,312,415, to Palermo, also shows a method for discharging numerous coils from a single pusher by use of a guidewire which has a section capable of interconnecting with the interior of the helically wound coil. U.S. Pat. No. 5,350,297, to Palermo et al., shows a pusher having a throat at its distal end and a pusher through its axis. The pusher sheath will hold onto the end of an embolic coil and will then be released upon pushing the axially placed pusher wire against the member found on the proximal end of the vaso-occlusive coil.
- Within electrolytically detachable vaso-occlusive devices, the vaso-occlusive portion of the assembly is attached to a pusher wire via a small electrolytically severable joint. The electrolytically severable joint is severed by the placement of an appropriate voltage on the core wire. The joint erodes in preference either to the vaso-occlusive device itself or to the pusher wire. In accordance with principles of competitive erosion, parts of the wire that are not intended to erode are often simply insulated to prevent such an electrolytic response caused by the imposition of the electrical current.
- U.S. Pat. Nos. 5,354,295 and its parent 5,122,136, both to Guglielmi et al., describe an electrolytically detachable embolic device. That is to say that a joint between the pusher wire and the vaso-occlusive portion dissolves or erodes when an electrical current is applied to the pusher wire.
- Some vaso-occlusive devices include specialized mechanical features and/or shapes. Various shaped coils have been described. For example, U.S. Pat. No. 5,624,461, to Mariant, describes a three-dimensional in-filling vaso-occlusive coil. U.S. Pat. No. 5,639,277, to Mariant et al., describes embolic coils having twisted helical shapes and U.S. Pat. No. 5,649,949, to Wallace et al., describes variable cross-section conical vaso-occlusive coils. A random shape is described, as well. U.S. Pat. No. 5,648,082, to Sung et al., describes methods for treating arrhythmia using coils which assume random configurations upon deployment from a catheter. U.S. Pat. No. 5,537,338 describes a multi-element intravascular occlusion device in which shaped coils may be employed. Spherical shaped occlusive devices are described in U.S. Pat. No. 5,645,558 to Horton. Horton describes how one or more strands can be wound to form a substantially hollow spherical or ovoid shape when deployed in a vessel. U.S. Pat. Nos. 5,690,666 and 5,718,711, by Berenstein et al., show a very flexible vaso-occlusive coil having little or no shape after introduction into the vascular space.
- One type of aneurysm commonly known as a “wide-neck aneurysm” is known to present particular difficulty in the placement and retention of vaso-occlusive devices. Furthermore, vaso-occlusive devices, in particular, vaso-occlusion coils, lacking substantial secondary shape strength may be difficult to maintain in position within an aneurysm no matter how skillfully they are placed.
- Vaso-occlusive devices are typically placed in an aneurysm in the following fashion. A micro-catheter is initially steered into or adjacent the entrance of an aneurysm, typically aided by the use of a steerable guide wire. Then either the guide wire is then withdrawn from the micro-catheter and replaced by the vaso-occlusive device or a separate catheter is delivered containing the vaso-occlusive device. The vaso-occlusive device is advanced through and out of a micro-catheter, desirably being completely delivered into the aneurysm. After, or perhaps, during, delivery of the device into the aneurysm, there is a risk that the device or a portion of the device might migrate out of the aneurysm entrance zone and into the feeding vessel. The presence of the device in the feeding vessel may cause the undesirable response of an occlusion in the feeding vessel. Also, there is a quantifiable risk that blood flow in the feeding vessel and the aneurysm may induce movement of the device further out of the aneurysm, resulting in a more developed embolus in the patent vessel.
- The utilization of a stent containing an outer layer of hydrogel has been presented in the art. As described, the stent can be placed in the parent vessel near the site of the aneurysm and allowed to hydrate. While potentially closing off the aneurysm neck this device unfortunately also unnecessarily seals off other parts of the vessel it contacts. This presents risks of creating stenosis or introducing emboli within the vessel. There exists a need for a device to bridge and seal the neck of the aneurysm thereby retaining the vaso-occlusive device within the aneurysm sac and allowing normal blood flow through the vessel.
- Another disclosed invention involves the use of hydrogel embolizing elements disposed concentrically on a filament and deployed within the aneurysm sac. Upon hydration the vaso-occlusive device expands to fill the space within the sac. Potentially the expansion of the device could extend out from the aneurysm and disrupt normal blood flow or create emboli. A need exists for a device to bridge the neck of the aneurysm thereby retaining the vaso-occlusive device within the aneurysm sac.
- As described, aneurysms present particularly acute medical risk due to the dangers associated with an inherently thin vascular wall. The utilization of vaso-occlusive devices to occlude an aneurysm without occluding the adjacent vasculature pose a special challenge. It is especially difficult when addressing wide neck aneurysms due to morphology, shape or herniation. There exists a need for a device to bridge and obstruct the wide necked aneurysms from within the aneurysm. None of the vaso-occlusive devices described above solve this problem.
- One aspect of the present invention pertains to a medical device for bridging, and at least partially obstructing, a neck portion of a vascular aneurysm. The medical device could be implantable and includes an apparatus having a base and at least one strut or lateral protrusion fixedly attached to the base. The apparatus, including the base and strut(s), is of a size and overall flexibility to lodge inside the aneurysm at the neck portion. A swellable material, such as hydrogel, is selectively applied to the strut(s) providing a therapeutic effect on the vascular aneurysm.
-
FIG. 1 is a side view of the retainer assembly. -
FIG. 2 is a side view of the retainer assembly with attached marker coils. -
FIG. 3 is a side view of an aneurysm emanating from the wall of a blood vessel. -
FIG. 4 is a partial sectioned view of the retainer assembly being inserted within the aneurysm sac. -
FIG. 5 is a side view of the retainer assembly lodged against the side wall of the aneurysm showing a coil having a swellable material attached in the vicinity of the aneurysm neck. -
FIG. 6 is a partial sectioned view of the retainer assembly as the vaso-occlusive catheter delivery device is positioned. -
FIG. 7 is a side view of the retainer assembly. -
FIG. 8 is a side view of the retainer assembly and illustrates the procedural elements associated with using the retainer assembly. -
FIG. 9 is a partial sectioned view of the aneurysm with both the retainer and vaso-occlusive devices inside the aneurysm. -
FIG. 10 is a perspective view of the aneurysm closed off. - This invention involves a device and procedure for solving the problem of material flow into and out of aneurysms. A retainer assembly is placed at the mouth of the aneurysm sac, forming a barrier for blood flow into the sac or migration of other devices, such as vaso-occlusive implants, out of the sac. Vaso-occlusive implants may be placed inside the sac for filling the unwanted space. The retainer assembly includes a swellable material placed on the spanning support framework to further close off the the aneurysm sac. The swellable material absorbs fluid upon contact with blood and expands in volume. The retainer assembly with the expanded swellable material seals off the neck of the aneurysm, preventing vaso-occlusive devices from migrating into the parent vessel. The following detailed description should be read with reference to the drawings in which like elements in different figures are numbered identically.
-
FIG. 1 illustrates aretainer assembly 10 with abase 20 and at least onestrut 30 extending from the base 20 laterally. Thebase 20 is preferably constructed of acoil 22 with a proximal and distal end and a lumen throughout. Thecoil 22 is preferably made from stainless steel, or other biocompatible material including shape memory polymers, and is approximately 0.017 inches in diameter and approximately 1.0 millimeter in length. Thebase 20 is centrally located when a plurality ofstruts 30 extend outwardly in different directions from thebase 20, as shown inFIG. 1 . Thebase 20 is connected to a delivery device at the proximal end of thecoil 22. -
Retainer assembly 10 includes lateral struts 30 that could either be round or flat wire, or any other construction that forms a scaffolding or bridge across the neck of the aneurysm. The diameter of the wires or ribbons making up thestrut elements 30 is preferably smaller than about 0.010 inches. Thestruts 30 may be produced from a number of materials such as metals, alloys, polymers, or other biocompatible medical device materials. Due to their desired expansion properties, superelastic alloys are commonly and desirably utilized in thestrut 30 construction. Superelastic alloys are well known in the art. Nitinol, which comprises the elements nickel and titanium, is one of the more well known super-elastic alloys. It is readily commercially available and undergoes the austenitic-martensitic-austenitic transformation in a variety of temperatures between −20C and +30C. - Although it is desirable that the
struts 30 of the current invention be made from superelastic alloys, other metals may in certain circumstances be appropriate. Such metals include a number of stainless steel materials and other highly elastic, if not superelastic alloys. Furthermore, it is within the scope of this invention that thestruts 30 be formed from polymeric materials. Such materials as polyethylene, polypropylene, various nylons, shape memory polymers, or polytetrafluoroethylene could be chosen along with a variety of other suitable polymeric materials which are biocompatible and fit the criteria necessary for this invention. - The
retainer assembly 10 has an overall shape which approximates that of the aneurysm neck in which it is placed. Specifically, theretainer assembly 10 has a number ofstruts 30 which extend from thebase 20, loop around and rejoin themselves to the base 20 forming a spanning support frame. The lateral struts 30 are connected to the distal end of the base by methods known to those skilled in the art, such as welding, crimping, adhesive bonding, or fusing. While the preferred embodiment, as shown inFIG. 1 , includesstruts 30 that loop around and connect to thebase 20, other types of lateral protrusions should be considered within the scope of the present invention.FIG. 1 illustratively includes threestruts 30, more or fewer could be utilized and are within the scope of the invention. - As shown, the
retainer assembly 10 including threestruts 30 creates a spanning “flower” shape. Although the illustrated struts 30 are generally shown to be approximately the same size and shape with respect to each other, this is not necessary. It is within the scope of this invention that theretainer assembly 10 be irregular in shape to fit within an irregularly shaped aneurysm. The length of thestruts 30 is generally appropriate to form a spanning element which contacts points along the inside of the aneurismal wall (further described inFIG. 5 ) and connects to thebase 20. While a certain minimal contact with the aneurysm wall is necessary to support the bridging struts 30 it is also possible for the retainer device to includestruts 30 which extend further along the inside wall of the aneurismal sac. - As shown in
FIG. 1 , thestruts 30 further contain anexpansible material 50, such as hydrogel, selectively attached for further occluding the aneurysm neck. Thematerial 50 is disposed on thestruts 30 in locations, as shown inFIG. 1 , which span and provide framework across the opening of the aneurysm sac. Upon hydration with time, thehydrogel 50 swells and effectively seals off the aneurysm by reducing the effective open area of the aneurysm neck. - The
absorbent material 50 is preferably formed of a polymeric colloidal system which is biocompatible. It may be a hydrogel or other such material with properties allowing it to swell and stabilize upon exposure to body fluids. Examples of hydrogels include gels formed from homopolymers, copolymers, and/or network polymers containing: polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylates, polymethacrylates, polyacrylamides, polyethyloxazoline, polysaccharides, mucopolysaccharides, polyaminoacids, carboxy alkyl celluloses, partially oxidized cellulose, hyaluronic acid, dextran, heparin sulfate, chondroitin sulfate, heparin, agar, starch, alginate, fibronectin, gelatin, collagen, fibrin, pectins, albumin, ovalbumin, polyesters of .alpha.-hydroxy acids including polyglycolic acid, poly-DL-lactic, poly-L-lactic acid, polylactones, polyanhydrides, polyorthoesters, polydioxanone, polycaprolactones, poly(delta-valerolactone), poly(gamma-butyrolactone), and combinations thereof. The gel may further comprises a chemical cross-linking agent having two or more reactive groups in order to form chemical bridges between two or more polymeric molecules, examples of cross-linking agents include diacrylates, oligoacrylates, dimethacrylates, oligomethacrylates, divinyl ethers, certain cations, and combinations thereof. - The
swellable material 50 can preferably be coated on thestruts 30 or array members of theretainer assembly 10 at the neck bridging locations. Alternatively, thehydrogel 50 may be fixed to thestruts 30 by a suitable biocompatible adhesive or other mechanical or chemical adhesion processes known in the art. These include spray or dip coating, chemical or plasma deposition or any other form of simple mechanical attachment or restriction. The preferred method will allow thehydrogel 50 material to remain permanently attached to thestruts 30 before, during and after delivery and hydration. The bonding method will allow expansion of theassembly 10 to its secondary shape without detrimental effects to the outer layer ofhydrogel 50. Thehydrogel 50 may be of a type that dissolves over time and may include growth factors or other biologic materials such as collagen or fibrin to facilitate thrombosis and cell infiltration. Bioactive materials may be incorporated into thehydrogel 50, including cytokines, growth factors, extracellular matrix molecules, proteins, enzymes, enzyme inhibitors, receptors, cells, polynucleic acids, lipid-based molecules, polysaccharides, drugs and fragments or combinations of these materials. Thehydrogel 50 may also incorporate radiopaque materials. - The distribution and arrangement of the
hydrogel matrix 50 on the array struts 30 covering the aneurysm neck may be controllable and shaped to allow certain sized objects, such as blood, to escape while trapping embolus or PVA particles if required. Thehydrogel 50 can also be used to effectively close off the neck area. A braid like structure or other pre-biased geometry, formed ofhydrogel 50, can be disposed on the array struts 30 and configured to expand outward from the struts to develop a sheet, or flat panel, as opposed to possibly expanding into the parent vessel and potentially occluding blood flow. Preferential expansion may also be accomplished by the use of coatings or elements within thehydrogel 50 which restrict expansion. Changes in pH or temperature, or other external activation methods, may be used to initiate the selectivelyexpandable hydrogel 50 in a certain direction or to a certain volume. - Marker coils 60 are constructed of radio-opaque material (ie. platinum) and assist in the guidance of the retainer assembly through a tubular delivery device and through a vascular system using radiography or fluoroscopy. In particular, the marker coils 60 facilitate positioning of the
bridge subassembly 10 within the aneurysm. The marker coils 60 may be placed at the site of overlapping struts 30, the base of theretainer assembly 20 or any location along thestrut 30 protrusions that assists in the placement of the assembly within the aneurysm. One embodiment, illustrated inFIG. 2 , includes a base 20 with amarker 60 attached to thecoil 22. Themarker 60 includes an inner 62 andouter marker coil 64. The ends of thestruts 30 are illustratively fixedly secured between theinner marker coil 62 andouter marker coil 64. The struts orlateral protrusions 30 may include marker coils 60, shown inFIG. 2 attached at the location where thestruts 30 overlap. The marker coils 60 may be added to the various elements of the device by methods known within the art such as plating, crimping or wrapping the element in a radio-opaque wire or ribbon. - In accordance with one embodiment of the invention, shown in
FIG. 1 , the proximal portion of thebase 20 is detachably connected to a severable joint 80 within acatheter 70. The severing action of the joint 80 enables theretainer assembly 10 to remain in a portion of theaneurysm 90 after thecatheter 70 has been removed from thevasculature 92. There are several means for actuating the severable joint 80 but for the purpose of simplifying the description, it will be assumed that the severable joint 80 is an electrolytic severable joint 80. -
FIG. 3 illustrates a cross sectioned view of ananeurysm 90 emanating from thewall 92 of a blood vessel. Acatheter 70 is shown inFIG. 4 delivering aretainer assembly 10. Theretainer assembly 10 is designed to fit inside acatheter 70 for delivery through thevasculature 92. As theretainer assembly 10 is contained in thecatheter 70 and delivered through the vascular 92 system it has a retracted or low profile shape. Theretainer assembly 10 is positioned at theneck 94, or opening of the aneurysm, as shown inFIG. 5 . Theretainer assembly 10 takes its secondary, or expanded, shape as it is pushed out of the distal end of thecatheter 70. - The
catheter 70, as shown inFIGS. 1 and 4 , contains a radio-opaque band orcoil 60 at its distal end. As is known in the art, radio-opaque band 60 assists in the guidance ofcatheter 70 through thevasculature 92 using fluoroscopy or radiology. As shown, the distal end ofcatheter 70 can be guided through the neck portion of theaneurysm 94. Once thecatheter 70 is inside theaneurysm 90 theretainer assembly 10 can be pushed out of the distal end of thecatheter 70 thus providing a device for aneurismal occlusion, as seen inFIG. 5 . - In order for the
retainer assembly 10 to be implanted in theaneurysm 90, thebase 20 must be detachably connected to acatheter 70, seeFIG. 5 . As stated, one method for detachment of the base 20 from thecatheter 70 is by activation of an electrolytically severable joint 80. The severable joint 80 connects the distal end of acore wire 75, as shown inFIG. 4 , to thebase 20 of theretainer assembly 10. The severable joint 80 and the action of releasing theretainer assembly 10, has been described in detail in U.S. Pat. No. 6,569,179, incorporated herein for reference. There are, of course, other means for detaching theretainer assembly 10 which should be considered within the scope of the invention. -
Retainer assembly 10 is further depicted inFIG. 5 showing placement against theside wall 96. Lateral struts 30 in combination withbase section 20 make up thebridge retainer assembly 10. While lateral struts orprotrusions 30 are illustratively wire loops, other types ofstruts 30 should be considered within the scope of the present invention. Thestruts 30 further contain anabsorbent material 50, such as hydrogel, selectively attached for further occluding theaneurysm neck 94. Upon hydration with time, thehydrogel 50 swells and effectively seals off theaneurysm neck 94. - With the
retainer assembly 10 in place against the inside of theaneurysm wall 94,FIGS. 6 and 7 show vaso-occlusive devices 77, such as vaso-occlusion coils, pushed through acatheter 70 andretainer assembly 10 inside theaneurysm 90. Coiling can be performed during expansion of thehydrogel 50 to stabilize the device within theaneurysm 90.FIGS. 8, 9 and 10 depict theaneurysm 90 filling with vaso-occlusive devices 77 while being retained by thebridge retainer assembly 10. - Those skilled in the art will recognize that the present invention may be altered and modified in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, it will be recognized that a variety of changes and modifications can be made without departing from the scope and spirit of the invention as described in the following claims.
Claims (37)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/990,163 US20060106421A1 (en) | 2004-11-16 | 2004-11-16 | Expansible neck bridge |
PCT/US2005/038276 WO2006055182A1 (en) | 2004-11-16 | 2005-10-21 | Expansible aneurism neck bridge |
EP05815173A EP1824396A1 (en) | 2004-11-16 | 2005-10-21 | Expansible aneurism neck bridge |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/990,163 US20060106421A1 (en) | 2004-11-16 | 2004-11-16 | Expansible neck bridge |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060106421A1 true US20060106421A1 (en) | 2006-05-18 |
Family
ID=35791003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/990,163 Abandoned US20060106421A1 (en) | 2004-11-16 | 2004-11-16 | Expansible neck bridge |
Country Status (3)
Country | Link |
---|---|
US (1) | US20060106421A1 (en) |
EP (1) | EP1824396A1 (en) |
WO (1) | WO2006055182A1 (en) |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050165379A1 (en) * | 2003-01-10 | 2005-07-28 | Mawad Michel E. | Microcatheter including swellable tip |
US20070100426A1 (en) * | 2004-03-31 | 2007-05-03 | Leon Rudakov | Medical device |
US20070100321A1 (en) * | 2004-12-22 | 2007-05-03 | Leon Rudakov | Medical device |
US20070191924A1 (en) * | 2004-03-21 | 2007-08-16 | Leon Rudakov | Method for treating aneurysms |
US20070255388A1 (en) * | 2004-03-31 | 2007-11-01 | Merlin Md Pte Ltd | Endovascular device with membrane |
US20090054966A1 (en) * | 2006-02-13 | 2009-02-26 | Merlin Md Pte Ltd. | Endovascular device with membrane |
WO2010011694A1 (en) * | 2008-07-22 | 2010-01-28 | Micro Therapeutics, Inc. | Vascular remodeling device |
US20100049165A1 (en) * | 2008-08-19 | 2010-02-25 | Micro Therapeutics, Inc | Detachable tip microcatheter |
US20100063582A1 (en) * | 2008-09-05 | 2010-03-11 | Merlin Md Pte Ltd | Endovascular device |
US20100160899A1 (en) * | 2008-12-10 | 2010-06-24 | Microvention, Inc. | Microcatheter |
US8066757B2 (en) | 2007-10-17 | 2011-11-29 | Mindframe, Inc. | Blood flow restoration and thrombus management methods |
US8088140B2 (en) | 2008-05-19 | 2012-01-03 | Mindframe, Inc. | Blood flow restorative and embolus removal methods |
US8333798B2 (en) | 2003-11-07 | 2012-12-18 | Merlin Md Pte Ltd. | Implantable medical devices with enhanced visibility, mechanical properties and biocompatability |
US8545514B2 (en) | 2008-04-11 | 2013-10-01 | Covidien Lp | Monorail neuro-microcatheter for delivery of medical devices to treat stroke, processes and products thereby |
US8585713B2 (en) | 2007-10-17 | 2013-11-19 | Covidien Lp | Expandable tip assembly for thrombus management |
US8679142B2 (en) | 2008-02-22 | 2014-03-25 | Covidien Lp | Methods and apparatus for flow restoration |
US8747597B2 (en) | 2008-04-21 | 2014-06-10 | Covidien Lp | Methods for making braid-ball occlusion devices |
US8926680B2 (en) | 2007-11-12 | 2015-01-06 | Covidien Lp | Aneurysm neck bridging processes with revascularization systems methods and products thereby |
US8926681B2 (en) | 2010-01-28 | 2015-01-06 | Covidien Lp | Vascular remodeling device |
US9060886B2 (en) | 2011-09-29 | 2015-06-23 | Covidien Lp | Vascular remodeling device |
US20150174381A1 (en) * | 2013-12-20 | 2015-06-25 | Microvention, Inc. | Expansile Member |
US9089332B2 (en) | 2011-03-25 | 2015-07-28 | Covidien Lp | Vascular remodeling device |
US9095342B2 (en) | 2009-11-09 | 2015-08-04 | Covidien Lp | Braid ball embolic device features |
US20150313606A1 (en) * | 2003-10-02 | 2015-11-05 | Lawrence Livermore National Security, Llc | Stent with expandable foam |
US9198687B2 (en) | 2007-10-17 | 2015-12-01 | Covidien Lp | Acute stroke revascularization/recanalization systems processes and products thereby |
US9220522B2 (en) | 2007-10-17 | 2015-12-29 | Covidien Lp | Embolus removal systems with baskets |
US9295571B2 (en) | 2013-01-17 | 2016-03-29 | Covidien Lp | Methods and apparatus for luminal stenting |
US9314248B2 (en) | 2012-11-06 | 2016-04-19 | Covidien Lp | Multi-pivot thrombectomy device |
US9393022B2 (en) | 2011-02-11 | 2016-07-19 | Covidien Lp | Two-stage deployment aneurysm embolization devices |
US9463105B2 (en) | 2013-03-14 | 2016-10-11 | Covidien Lp | Methods and apparatus for luminal stenting |
US9468442B2 (en) | 2010-01-28 | 2016-10-18 | Covidien Lp | Vascular remodeling device |
US9848906B1 (en) | 2017-06-20 | 2017-12-26 | Joe Michael Eskridge | Stent retriever having an expandable fragment guard |
US9884172B2 (en) | 2011-02-25 | 2018-02-06 | Microvention, Inc. | Reinforced balloon catheter |
US9962146B2 (en) | 2015-01-20 | 2018-05-08 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US10123803B2 (en) | 2007-10-17 | 2018-11-13 | Covidien Lp | Methods of managing neurovascular obstructions |
US10124087B2 (en) | 2012-06-19 | 2018-11-13 | Covidien Lp | Detachable coupling for catheter |
US10327781B2 (en) | 2012-11-13 | 2019-06-25 | Covidien Lp | Occlusive devices |
US10420563B2 (en) | 2016-07-08 | 2019-09-24 | Neurogami Medical, Inc. | Delivery system insertable through body lumen |
US10478194B2 (en) | 2015-09-23 | 2019-11-19 | Covidien Lp | Occlusive devices |
US10722255B2 (en) | 2008-12-23 | 2020-07-28 | Covidien Lp | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
US10736730B2 (en) | 2015-01-20 | 2020-08-11 | Neurogami Medical, Inc. | Vascular implant |
US10736758B2 (en) | 2013-03-15 | 2020-08-11 | Covidien | Occlusive device |
US10857012B2 (en) | 2015-01-20 | 2020-12-08 | Neurogami Medical, Inc. | Vascular implant |
CN112135570A (en) * | 2018-04-10 | 2020-12-25 | 美得思达健康公司 | Embolic stent device |
US20200405347A1 (en) * | 2016-12-05 | 2020-12-31 | Daniel Ezra Walzman, III | Mesh cap for ameliorating outpouchings |
US10905430B2 (en) | 2018-01-24 | 2021-02-02 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US10925611B2 (en) | 2015-01-20 | 2021-02-23 | Neurogami Medical, Inc. | Packaging for surgical implant |
US10939915B2 (en) | 2018-05-31 | 2021-03-09 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US10987208B2 (en) | 2012-04-06 | 2021-04-27 | Merlin Md Pte Ltd. | Devices and methods for treating an aneurysm |
US11058430B2 (en) | 2018-05-25 | 2021-07-13 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US11076860B2 (en) | 2014-03-31 | 2021-08-03 | DePuy Synthes Products, Inc. | Aneurysm occlusion device |
US11076861B2 (en) | 2018-10-12 | 2021-08-03 | DePuy Synthes Products, Inc. | Folded aneurysm treatment device and delivery method |
US11123077B2 (en) | 2018-09-25 | 2021-09-21 | DePuy Synthes Products, Inc. | Intrasaccular device positioning and deployment system |
US11134953B2 (en) | 2019-02-06 | 2021-10-05 | DePuy Synthes Products, Inc. | Adhesive cover occluding device for aneurysm treatment |
US11154302B2 (en) | 2014-03-31 | 2021-10-26 | DePuy Synthes Products, Inc. | Aneurysm occlusion device |
US11272939B2 (en) | 2018-12-18 | 2022-03-15 | DePuy Synthes Products, Inc. | Intrasaccular flow diverter for treating cerebral aneurysms |
US11278292B2 (en) | 2019-05-21 | 2022-03-22 | DePuy Synthes Products, Inc. | Inverting braided aneurysm treatment system and method |
US11337706B2 (en) | 2019-03-27 | 2022-05-24 | DePuy Synthes Products, Inc. | Aneurysm treatment device |
US11337714B2 (en) | 2007-10-17 | 2022-05-24 | Covidien Lp | Restoring blood flow and clot removal during acute ischemic stroke |
US11406392B2 (en) | 2018-12-12 | 2022-08-09 | DePuy Synthes Products, Inc. | Aneurysm occluding device for use with coagulating agents |
US11413046B2 (en) | 2019-05-21 | 2022-08-16 | DePuy Synthes Products, Inc. | Layered braided aneurysm treatment device |
US11457926B2 (en) | 2019-12-18 | 2022-10-04 | DePuy Synthes Products, Inc. | Implant having an intrasaccular section and intravascular section |
US11484319B2 (en) | 2015-01-20 | 2022-11-01 | Neurogami Medical, Inc. | Delivery system for micrograft for treating intracranial aneurysms |
US11497504B2 (en) | 2019-05-21 | 2022-11-15 | DePuy Synthes Products, Inc. | Aneurysm treatment with pushable implanted braid |
US11583282B2 (en) | 2019-05-21 | 2023-02-21 | DePuy Synthes Products, Inc. | Layered braided aneurysm treatment device |
US11583288B2 (en) | 2018-08-08 | 2023-02-21 | DePuy Synthes Products, Inc. | Delivery of embolic braid |
US11596412B2 (en) | 2018-05-25 | 2023-03-07 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US11602350B2 (en) | 2019-12-05 | 2023-03-14 | DePuy Synthes Products, Inc. | Intrasaccular inverting braid with highly flexible fill material |
US11607226B2 (en) | 2019-05-21 | 2023-03-21 | DePuy Synthes Products, Inc. | Layered braided aneurysm treatment device with corrugations |
US11633818B2 (en) | 2019-11-04 | 2023-04-25 | Covidien Lp | Devices, systems, and methods for treatment of intracranial aneurysms |
US11672543B2 (en) | 2017-02-23 | 2023-06-13 | DePuy Synthes Products, Inc. | Aneurysm method and system |
US11672542B2 (en) | 2019-05-21 | 2023-06-13 | DePuy Synthes Products, Inc. | Aneurysm treatment with pushable ball segment |
US11707371B2 (en) | 2008-05-13 | 2023-07-25 | Covidien Lp | Braid implant delivery systems |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105943208B (en) | 2007-06-25 | 2019-02-15 | 微仙美国有限公司 | Self-expanding prosthesis |
Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US4994098A (en) * | 1990-02-02 | 1991-02-19 | Air Products And Chemicals, Inc. | Production of oxygen-lean argon from air |
US5122136A (en) * | 1990-03-13 | 1992-06-16 | The Regents Of The University Of California | Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US5122158A (en) * | 1981-07-16 | 1992-06-16 | Kao Corporation | Process for cleaning clothes |
US5234457A (en) * | 1991-10-09 | 1993-08-10 | Boston Scientific Corporation | Impregnated stent |
US5234437A (en) * | 1991-12-12 | 1993-08-10 | Target Therapeutics, Inc. | Detachable pusher-vasoocclusion coil assembly with threaded coupling |
US5250071A (en) * | 1992-09-22 | 1993-10-05 | Target Therapeutics, Inc. | Detachable embolic coil assembly using interlocking clasps and method of use |
US5258042A (en) * | 1991-12-16 | 1993-11-02 | Henry Ford Health System | Intravascular hydrogel implant |
US5261195A (en) * | 1991-10-18 | 1993-11-16 | Savetime Corporation | Roof water dispersal system |
US5281105A (en) * | 1992-04-06 | 1994-01-25 | Matsushita Refrigeration Company | Hermetic compressor |
US5312415A (en) * | 1992-09-22 | 1994-05-17 | Target Therapeutics, Inc. | Assembly for placement of embolic coils using frictional placement |
US5324295A (en) * | 1992-04-24 | 1994-06-28 | Shapiro Michael R | Drill guide for surgical pins |
US5340967A (en) * | 1991-09-24 | 1994-08-23 | Tidel Engineering, Inc. | Method for storing and dispensing cash |
US5350297A (en) * | 1991-12-24 | 1994-09-27 | Cohen Robert N | Method and apparatus for recording the position of dental implants |
US5537338A (en) * | 1993-11-24 | 1996-07-16 | Intel Corporation | Process and apparatus for bitwise tracking in a byte-based computer system |
US5624461A (en) * | 1995-06-06 | 1997-04-29 | Target Therapeutics, Inc. | Three dimensional in-filling vaso-occlusive coils |
US5639277A (en) * | 1995-04-28 | 1997-06-17 | Target Therapeutics, Inc. | Embolic coils with offset helical and twisted helical shapes |
US5645558A (en) * | 1995-04-20 | 1997-07-08 | Medical University Of South Carolina | Anatomically shaped vasoocclusive device and method of making the same |
US5648082A (en) * | 1991-02-21 | 1997-07-15 | University Of South Alabama | Polyamino acid dispersants |
US5649949A (en) * | 1996-03-14 | 1997-07-22 | Target Therapeutics, Inc. | Variable cross-section conical vasoocclusive coils |
US5688077A (en) * | 1993-08-30 | 1997-11-18 | Cape Town Iron And Steel Works (Pty) Limited | Rock anchor bolt |
US5690666A (en) * | 1992-11-18 | 1997-11-25 | Target Therapeutics, Inc. | Ultrasoft embolism coils and process for using them |
US5815858A (en) * | 1996-09-16 | 1998-10-06 | Cross Island Trading Co., Inc. | Slot and post front operating futon |
US5824481A (en) * | 1993-06-25 | 1998-10-20 | Hitachi, Ltd. | DNA analyzing method |
US5848062A (en) * | 1996-04-02 | 1998-12-08 | Nec Corporation | Wireless communication equipment for remote station |
US5900948A (en) * | 1994-12-21 | 1999-05-04 | Canon Kabushiki Kaisha | Image processing apparatus and method |
US5910940A (en) * | 1996-10-08 | 1999-06-08 | Polaroid Corporation | Storage medium having a layer of micro-optical lenses each lens generating an evanescent field |
US5935148A (en) * | 1998-06-24 | 1999-08-10 | Target Therapeutics, Inc. | Detachable, varying flexibility, aneurysm neck bridge |
US6036720A (en) * | 1997-12-15 | 2000-03-14 | Target Therapeutics, Inc. | Sheet metal aneurysm neck bridge |
US6086577A (en) * | 1997-08-13 | 2000-07-11 | Scimed Life Systems, Inc. | Detachable aneurysm neck bridge (III) |
US6113629A (en) * | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
US6200818B1 (en) * | 1997-12-23 | 2001-03-13 | Evotec Biosystems Ag | Method for detecting reactions by means of coincidence analysis |
US6238403B1 (en) * | 1999-10-04 | 2001-05-29 | Microvention, Inc. | Filamentous embolic device with expansible elements |
US6312421B1 (en) * | 1999-07-23 | 2001-11-06 | Neurovasx, Inc. | Aneurysm embolization material and device |
US6383174B1 (en) * | 1997-08-05 | 2002-05-07 | Scimed Life Systems, Inc. | Detachable aneurysm neck bridge (II) |
US6569179B2 (en) * | 1998-11-10 | 2003-05-27 | Scimed Life Systems, Inc. | Bioactive three loop coil |
US20040044391A1 (en) * | 2002-08-29 | 2004-03-04 | Stephen Porter | Device for closure of a vascular defect and method of treating the same |
US20040044981A1 (en) * | 2002-09-02 | 2004-03-04 | Nec Corportion | Reticle fabrication method |
US20040098027A1 (en) * | 2001-07-31 | 2004-05-20 | Scimed Life Systems, Inc. | Expandable body cavity liner device |
-
2004
- 2004-11-16 US US10/990,163 patent/US20060106421A1/en not_active Abandoned
-
2005
- 2005-10-21 EP EP05815173A patent/EP1824396A1/en not_active Withdrawn
- 2005-10-21 WO PCT/US2005/038276 patent/WO2006055182A1/en not_active Application Discontinuation
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122158A (en) * | 1981-07-16 | 1992-06-16 | Kao Corporation | Process for cleaning clothes |
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US4994098A (en) * | 1990-02-02 | 1991-02-19 | Air Products And Chemicals, Inc. | Production of oxygen-lean argon from air |
US5122136A (en) * | 1990-03-13 | 1992-06-16 | The Regents Of The University Of California | Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US5648082A (en) * | 1991-02-21 | 1997-07-15 | University Of South Alabama | Polyamino acid dispersants |
US5340967A (en) * | 1991-09-24 | 1994-08-23 | Tidel Engineering, Inc. | Method for storing and dispensing cash |
US5234457A (en) * | 1991-10-09 | 1993-08-10 | Boston Scientific Corporation | Impregnated stent |
US5261195A (en) * | 1991-10-18 | 1993-11-16 | Savetime Corporation | Roof water dispersal system |
US5234437A (en) * | 1991-12-12 | 1993-08-10 | Target Therapeutics, Inc. | Detachable pusher-vasoocclusion coil assembly with threaded coupling |
US5258042A (en) * | 1991-12-16 | 1993-11-02 | Henry Ford Health System | Intravascular hydrogel implant |
US5350297A (en) * | 1991-12-24 | 1994-09-27 | Cohen Robert N | Method and apparatus for recording the position of dental implants |
US5281105A (en) * | 1992-04-06 | 1994-01-25 | Matsushita Refrigeration Company | Hermetic compressor |
US5324295A (en) * | 1992-04-24 | 1994-06-28 | Shapiro Michael R | Drill guide for surgical pins |
US5312415A (en) * | 1992-09-22 | 1994-05-17 | Target Therapeutics, Inc. | Assembly for placement of embolic coils using frictional placement |
US5250071A (en) * | 1992-09-22 | 1993-10-05 | Target Therapeutics, Inc. | Detachable embolic coil assembly using interlocking clasps and method of use |
US5718711A (en) * | 1992-11-18 | 1998-02-17 | Target Therapeutics, Inc. | Ultrasoft embolism devices and process for using them |
US5690666A (en) * | 1992-11-18 | 1997-11-25 | Target Therapeutics, Inc. | Ultrasoft embolism coils and process for using them |
US5824481A (en) * | 1993-06-25 | 1998-10-20 | Hitachi, Ltd. | DNA analyzing method |
US5688077A (en) * | 1993-08-30 | 1997-11-18 | Cape Town Iron And Steel Works (Pty) Limited | Rock anchor bolt |
US5537338A (en) * | 1993-11-24 | 1996-07-16 | Intel Corporation | Process and apparatus for bitwise tracking in a byte-based computer system |
US5900948A (en) * | 1994-12-21 | 1999-05-04 | Canon Kabushiki Kaisha | Image processing apparatus and method |
US5645558A (en) * | 1995-04-20 | 1997-07-08 | Medical University Of South Carolina | Anatomically shaped vasoocclusive device and method of making the same |
US5639277A (en) * | 1995-04-28 | 1997-06-17 | Target Therapeutics, Inc. | Embolic coils with offset helical and twisted helical shapes |
US5624461A (en) * | 1995-06-06 | 1997-04-29 | Target Therapeutics, Inc. | Three dimensional in-filling vaso-occlusive coils |
US5649949A (en) * | 1996-03-14 | 1997-07-22 | Target Therapeutics, Inc. | Variable cross-section conical vasoocclusive coils |
US5848062A (en) * | 1996-04-02 | 1998-12-08 | Nec Corporation | Wireless communication equipment for remote station |
US5815858A (en) * | 1996-09-16 | 1998-10-06 | Cross Island Trading Co., Inc. | Slot and post front operating futon |
US5910940A (en) * | 1996-10-08 | 1999-06-08 | Polaroid Corporation | Storage medium having a layer of micro-optical lenses each lens generating an evanescent field |
US6383174B1 (en) * | 1997-08-05 | 2002-05-07 | Scimed Life Systems, Inc. | Detachable aneurysm neck bridge (II) |
US6086577A (en) * | 1997-08-13 | 2000-07-11 | Scimed Life Systems, Inc. | Detachable aneurysm neck bridge (III) |
US6036720A (en) * | 1997-12-15 | 2000-03-14 | Target Therapeutics, Inc. | Sheet metal aneurysm neck bridge |
US6200818B1 (en) * | 1997-12-23 | 2001-03-13 | Evotec Biosystems Ag | Method for detecting reactions by means of coincidence analysis |
US6113629A (en) * | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
US5935148A (en) * | 1998-06-24 | 1999-08-10 | Target Therapeutics, Inc. | Detachable, varying flexibility, aneurysm neck bridge |
US6569179B2 (en) * | 1998-11-10 | 2003-05-27 | Scimed Life Systems, Inc. | Bioactive three loop coil |
US6312421B1 (en) * | 1999-07-23 | 2001-11-06 | Neurovasx, Inc. | Aneurysm embolization material and device |
US6238403B1 (en) * | 1999-10-04 | 2001-05-29 | Microvention, Inc. | Filamentous embolic device with expansible elements |
US6299619B1 (en) * | 1999-10-04 | 2001-10-09 | Microvention, Inc. | Methods for embolizing a target vascular site |
US20040098027A1 (en) * | 2001-07-31 | 2004-05-20 | Scimed Life Systems, Inc. | Expandable body cavity liner device |
US20040044391A1 (en) * | 2002-08-29 | 2004-03-04 | Stephen Porter | Device for closure of a vascular defect and method of treating the same |
US20040044981A1 (en) * | 2002-09-02 | 2004-03-04 | Nec Corportion | Reticle fabrication method |
Cited By (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080208160A9 (en) * | 2003-01-10 | 2008-08-28 | Mawad Michel E | Microcatheter including swellable tip |
US20050165379A1 (en) * | 2003-01-10 | 2005-07-28 | Mawad Michel E. | Microcatheter including swellable tip |
US20080294104A1 (en) * | 2003-01-10 | 2008-11-27 | Mawad Michel E | Microcatheter Including Swellable Tip |
US10806561B2 (en) | 2003-10-02 | 2020-10-20 | Lawrence Livermore National Security, Llc | Stent with expandable foam |
US10080642B2 (en) * | 2003-10-02 | 2018-09-25 | Lawrence Livermore National Security, Llc | Stent with expandable foam |
US11864989B2 (en) | 2003-10-02 | 2024-01-09 | Lawrence Livermore National Security, Llc | Stent with expandable foam |
US20150313606A1 (en) * | 2003-10-02 | 2015-11-05 | Lawrence Livermore National Security, Llc | Stent with expandable foam |
US8333798B2 (en) | 2003-11-07 | 2012-12-18 | Merlin Md Pte Ltd. | Implantable medical devices with enhanced visibility, mechanical properties and biocompatability |
US20070191924A1 (en) * | 2004-03-21 | 2007-08-16 | Leon Rudakov | Method for treating aneurysms |
US10390934B2 (en) | 2004-03-31 | 2019-08-27 | Merlin Md Pte. Ltd. | Medical device |
US11033378B2 (en) | 2004-03-31 | 2021-06-15 | Merlin Md Pte Ltd. | Medical device |
US20070100426A1 (en) * | 2004-03-31 | 2007-05-03 | Leon Rudakov | Medical device |
US9844433B2 (en) | 2004-03-31 | 2017-12-19 | Merlin Md Pte. Ltd. | Medical device |
US9585668B2 (en) | 2004-03-31 | 2017-03-07 | Merlin Md Pte Ltd | Medical device |
US9433518B2 (en) | 2004-03-31 | 2016-09-06 | Merlin Md Pte. Ltd. | Medical device |
US8715340B2 (en) | 2004-03-31 | 2014-05-06 | Merlin Md Pte Ltd. | Endovascular device with membrane |
US20070255388A1 (en) * | 2004-03-31 | 2007-11-01 | Merlin Md Pte Ltd | Endovascular device with membrane |
US8500751B2 (en) | 2004-03-31 | 2013-08-06 | Merlin Md Pte Ltd | Medical device |
US8920430B2 (en) | 2004-03-31 | 2014-12-30 | Merlin Md Pte. Ltd. | Medical device |
US8915952B2 (en) | 2004-03-31 | 2014-12-23 | Merlin Md Pte Ltd. | Method for treating aneurysms |
US20070100321A1 (en) * | 2004-12-22 | 2007-05-03 | Leon Rudakov | Medical device |
US20090054966A1 (en) * | 2006-02-13 | 2009-02-26 | Merlin Md Pte Ltd. | Endovascular device with membrane |
US9198687B2 (en) | 2007-10-17 | 2015-12-01 | Covidien Lp | Acute stroke revascularization/recanalization systems processes and products thereby |
US8197493B2 (en) | 2007-10-17 | 2012-06-12 | Mindframe, Inc. | Method for providing progressive therapy for thrombus management |
US10016211B2 (en) | 2007-10-17 | 2018-07-10 | Covidien Lp | Expandable tip assembly for thrombus management |
US8585713B2 (en) | 2007-10-17 | 2013-11-19 | Covidien Lp | Expandable tip assembly for thrombus management |
US8574262B2 (en) | 2007-10-17 | 2013-11-05 | Covidien Lp | Revascularization devices |
US10123803B2 (en) | 2007-10-17 | 2018-11-13 | Covidien Lp | Methods of managing neurovascular obstructions |
US8066757B2 (en) | 2007-10-17 | 2011-11-29 | Mindframe, Inc. | Blood flow restoration and thrombus management methods |
US8070791B2 (en) | 2007-10-17 | 2011-12-06 | Mindframe, Inc. | Multiple layer embolus removal |
US8945143B2 (en) | 2007-10-17 | 2015-02-03 | Covidien Lp | Expandable tip assembly for thrombus management |
US8945172B2 (en) | 2007-10-17 | 2015-02-03 | Covidien Lp | Devices for restoring blood flow and clot removal during acute ischemic stroke |
US10835257B2 (en) | 2007-10-17 | 2020-11-17 | Covidien Lp | Methods of managing neurovascular obstructions |
US11337714B2 (en) | 2007-10-17 | 2022-05-24 | Covidien Lp | Restoring blood flow and clot removal during acute ischemic stroke |
US11786254B2 (en) | 2007-10-17 | 2023-10-17 | Covidien Lp | Methods of managing neurovascular obstructions |
US9387098B2 (en) | 2007-10-17 | 2016-07-12 | Covidien Lp | Revascularization devices |
US10413310B2 (en) | 2007-10-17 | 2019-09-17 | Covidien Lp | Restoring blood flow and clot removal during acute ischemic stroke |
US9320532B2 (en) | 2007-10-17 | 2016-04-26 | Covidien Lp | Expandable tip assembly for thrombus management |
US9220522B2 (en) | 2007-10-17 | 2015-12-29 | Covidien Lp | Embolus removal systems with baskets |
US8926680B2 (en) | 2007-11-12 | 2015-01-06 | Covidien Lp | Aneurysm neck bridging processes with revascularization systems methods and products thereby |
US11529156B2 (en) | 2008-02-22 | 2022-12-20 | Covidien Lp | Methods and apparatus for flow restoration |
US8679142B2 (en) | 2008-02-22 | 2014-03-25 | Covidien Lp | Methods and apparatus for flow restoration |
US9161766B2 (en) | 2008-02-22 | 2015-10-20 | Covidien Lp | Methods and apparatus for flow restoration |
US8940003B2 (en) | 2008-02-22 | 2015-01-27 | Covidien Lp | Methods and apparatus for flow restoration |
US10456151B2 (en) | 2008-02-22 | 2019-10-29 | Covidien Lp | Methods and apparatus for flow restoration |
US8545514B2 (en) | 2008-04-11 | 2013-10-01 | Covidien Lp | Monorail neuro-microcatheter for delivery of medical devices to treat stroke, processes and products thereby |
US9585669B2 (en) | 2008-04-21 | 2017-03-07 | Covidien Lp | Multiple layer filamentary devices for treatment of vascular defects |
US9039726B2 (en) | 2008-04-21 | 2015-05-26 | Covidien Lp | Filamentary devices for treatment of vascular defects |
US8747597B2 (en) | 2008-04-21 | 2014-06-10 | Covidien Lp | Methods for making braid-ball occlusion devices |
US11844528B2 (en) | 2008-04-21 | 2023-12-19 | Covidien Lp | Multiple layer filamentary devices for treatment of vascular defects |
US11707371B2 (en) | 2008-05-13 | 2023-07-25 | Covidien Lp | Braid implant delivery systems |
US8088140B2 (en) | 2008-05-19 | 2012-01-03 | Mindframe, Inc. | Blood flow restorative and embolus removal methods |
WO2010011694A1 (en) * | 2008-07-22 | 2010-01-28 | Micro Therapeutics, Inc. | Vascular remodeling device |
US9179918B2 (en) | 2008-07-22 | 2015-11-10 | Covidien Lp | Vascular remodeling device |
US9468739B2 (en) | 2008-08-19 | 2016-10-18 | Covidien Lp | Detachable tip microcatheter |
US10512469B2 (en) | 2008-08-19 | 2019-12-24 | Covidien Lp | Detachable tip microcatheter |
US20100049165A1 (en) * | 2008-08-19 | 2010-02-25 | Micro Therapeutics, Inc | Detachable tip microcatheter |
US11457927B2 (en) | 2008-08-19 | 2022-10-04 | Covidien Lp | Detachable tip microcatheter |
US9486608B2 (en) | 2008-08-19 | 2016-11-08 | Covidien Lp | Detachable tip microcatheter |
US8262692B2 (en) | 2008-09-05 | 2012-09-11 | Merlin Md Pte Ltd | Endovascular device |
US20100063582A1 (en) * | 2008-09-05 | 2010-03-11 | Merlin Md Pte Ltd | Endovascular device |
US20100160899A1 (en) * | 2008-12-10 | 2010-06-24 | Microvention, Inc. | Microcatheter |
US8992506B2 (en) | 2008-12-10 | 2015-03-31 | MircoVention, Inc. | Microcatheter |
US10722255B2 (en) | 2008-12-23 | 2020-07-28 | Covidien Lp | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
US9095342B2 (en) | 2009-11-09 | 2015-08-04 | Covidien Lp | Braid ball embolic device features |
US9468442B2 (en) | 2010-01-28 | 2016-10-18 | Covidien Lp | Vascular remodeling device |
US8926681B2 (en) | 2010-01-28 | 2015-01-06 | Covidien Lp | Vascular remodeling device |
US9393022B2 (en) | 2011-02-11 | 2016-07-19 | Covidien Lp | Two-stage deployment aneurysm embolization devices |
US9884172B2 (en) | 2011-02-25 | 2018-02-06 | Microvention, Inc. | Reinforced balloon catheter |
US10967156B2 (en) | 2011-02-25 | 2021-04-06 | Microvention, Inc. | Reinforced balloon catheter |
US11147563B2 (en) | 2011-03-25 | 2021-10-19 | Covidien Lp | Vascular remodeling device |
US10004511B2 (en) | 2011-03-25 | 2018-06-26 | Covidien Lp | Vascular remodeling device |
US9089332B2 (en) | 2011-03-25 | 2015-07-28 | Covidien Lp | Vascular remodeling device |
US9060886B2 (en) | 2011-09-29 | 2015-06-23 | Covidien Lp | Vascular remodeling device |
US11654037B2 (en) | 2011-09-29 | 2023-05-23 | Covidien Lp | Vascular remodeling device |
US10828182B2 (en) | 2011-09-29 | 2020-11-10 | Covidien Lp | Vascular remodeling device |
US10987208B2 (en) | 2012-04-06 | 2021-04-27 | Merlin Md Pte Ltd. | Devices and methods for treating an aneurysm |
US10124087B2 (en) | 2012-06-19 | 2018-11-13 | Covidien Lp | Detachable coupling for catheter |
US9314248B2 (en) | 2012-11-06 | 2016-04-19 | Covidien Lp | Multi-pivot thrombectomy device |
US11406405B2 (en) | 2012-11-06 | 2022-08-09 | Covidien Lp | Multi-pivot thrombectomy device |
US9924959B2 (en) | 2012-11-06 | 2018-03-27 | Covidien Lp | Multi-pivot thrombectomy device |
US10327781B2 (en) | 2012-11-13 | 2019-06-25 | Covidien Lp | Occlusive devices |
US11786253B2 (en) | 2012-11-13 | 2023-10-17 | Covidien Lp | Occlusive devices |
US11690628B2 (en) | 2012-11-13 | 2023-07-04 | Covidien Lp | Occlusive devices |
US9901472B2 (en) | 2013-01-17 | 2018-02-27 | Covidien Lp | Methods and apparatus for luminal stenting |
US9295571B2 (en) | 2013-01-17 | 2016-03-29 | Covidien Lp | Methods and apparatus for luminal stenting |
US9463105B2 (en) | 2013-03-14 | 2016-10-11 | Covidien Lp | Methods and apparatus for luminal stenting |
US10736758B2 (en) | 2013-03-15 | 2020-08-11 | Covidien | Occlusive device |
US11389309B2 (en) | 2013-03-15 | 2022-07-19 | Covidien Lp | Occlusive device |
US10045786B2 (en) * | 2013-12-20 | 2018-08-14 | Microvention, Inc. | Expansile member |
US20150174381A1 (en) * | 2013-12-20 | 2015-06-25 | Microvention, Inc. | Expansile Member |
US11426175B2 (en) | 2013-12-20 | 2022-08-30 | Microvention, Inc. | Expansile member |
US11154302B2 (en) | 2014-03-31 | 2021-10-26 | DePuy Synthes Products, Inc. | Aneurysm occlusion device |
US11076860B2 (en) | 2014-03-31 | 2021-08-03 | DePuy Synthes Products, Inc. | Aneurysm occlusion device |
US10285678B2 (en) | 2015-01-20 | 2019-05-14 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US11786255B2 (en) | 2015-01-20 | 2023-10-17 | Neurogami Medical, Inc | Packaging for surgical implant |
US11627950B2 (en) | 2015-01-20 | 2023-04-18 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US10299775B2 (en) | 2015-01-20 | 2019-05-28 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US10925611B2 (en) | 2015-01-20 | 2021-02-23 | Neurogami Medical, Inc. | Packaging for surgical implant |
US9999413B2 (en) | 2015-01-20 | 2018-06-19 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US11096679B2 (en) | 2015-01-20 | 2021-08-24 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US11484319B2 (en) | 2015-01-20 | 2022-11-01 | Neurogami Medical, Inc. | Delivery system for micrograft for treating intracranial aneurysms |
US9962146B2 (en) | 2015-01-20 | 2018-05-08 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US11006940B2 (en) | 2015-01-20 | 2021-05-18 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US10285679B2 (en) | 2015-01-20 | 2019-05-14 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US10857012B2 (en) | 2015-01-20 | 2020-12-08 | Neurogami Medical, Inc. | Vascular implant |
US11241223B2 (en) | 2015-01-20 | 2022-02-08 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US10653403B2 (en) | 2015-01-20 | 2020-05-19 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US10736730B2 (en) | 2015-01-20 | 2020-08-11 | Neurogami Medical, Inc. | Vascular implant |
US10799225B2 (en) | 2015-01-20 | 2020-10-13 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US11779452B2 (en) | 2015-01-20 | 2023-10-10 | Neurogami Medical, Inc. | Vascular implant |
US10231722B2 (en) | 2015-01-20 | 2019-03-19 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
US11357510B2 (en) | 2015-09-23 | 2022-06-14 | Covidien Lp | Occlusive devices |
US10478194B2 (en) | 2015-09-23 | 2019-11-19 | Covidien Lp | Occlusive devices |
US10420563B2 (en) | 2016-07-08 | 2019-09-24 | Neurogami Medical, Inc. | Delivery system insertable through body lumen |
US20200405347A1 (en) * | 2016-12-05 | 2020-12-31 | Daniel Ezra Walzman, III | Mesh cap for ameliorating outpouchings |
US11890020B2 (en) | 2017-02-23 | 2024-02-06 | DePuy Synthes Products, Inc. | Intrasaccular aneurysm treatment device with varying coatings |
US11672543B2 (en) | 2017-02-23 | 2023-06-13 | DePuy Synthes Products, Inc. | Aneurysm method and system |
US11266435B2 (en) | 2017-06-20 | 2022-03-08 | Joe Michael Eskridge | Stent retriever having an expandable fragment guard |
US9848906B1 (en) | 2017-06-20 | 2017-12-26 | Joe Michael Eskridge | Stent retriever having an expandable fragment guard |
US11672540B2 (en) | 2018-01-24 | 2023-06-13 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US10905430B2 (en) | 2018-01-24 | 2021-02-02 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US11103253B2 (en) | 2018-04-10 | 2021-08-31 | Medstar Health | Embolization scaffold devices |
CN112135570A (en) * | 2018-04-10 | 2020-12-25 | 美得思达健康公司 | Embolic stent device |
US11058430B2 (en) | 2018-05-25 | 2021-07-13 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US11596412B2 (en) | 2018-05-25 | 2023-03-07 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US10939915B2 (en) | 2018-05-31 | 2021-03-09 | DePuy Synthes Products, Inc. | Aneurysm device and delivery system |
US11583288B2 (en) | 2018-08-08 | 2023-02-21 | DePuy Synthes Products, Inc. | Delivery of embolic braid |
US11123077B2 (en) | 2018-09-25 | 2021-09-21 | DePuy Synthes Products, Inc. | Intrasaccular device positioning and deployment system |
US11076861B2 (en) | 2018-10-12 | 2021-08-03 | DePuy Synthes Products, Inc. | Folded aneurysm treatment device and delivery method |
US11633191B2 (en) | 2018-10-12 | 2023-04-25 | DePuy Synthes Products, Inc. | Folded aneurysm treatment device and delivery method |
US11406392B2 (en) | 2018-12-12 | 2022-08-09 | DePuy Synthes Products, Inc. | Aneurysm occluding device for use with coagulating agents |
US11272939B2 (en) | 2018-12-18 | 2022-03-15 | DePuy Synthes Products, Inc. | Intrasaccular flow diverter for treating cerebral aneurysms |
US11134953B2 (en) | 2019-02-06 | 2021-10-05 | DePuy Synthes Products, Inc. | Adhesive cover occluding device for aneurysm treatment |
US11337706B2 (en) | 2019-03-27 | 2022-05-24 | DePuy Synthes Products, Inc. | Aneurysm treatment device |
US11413046B2 (en) | 2019-05-21 | 2022-08-16 | DePuy Synthes Products, Inc. | Layered braided aneurysm treatment device |
US11672542B2 (en) | 2019-05-21 | 2023-06-13 | DePuy Synthes Products, Inc. | Aneurysm treatment with pushable ball segment |
US11278292B2 (en) | 2019-05-21 | 2022-03-22 | DePuy Synthes Products, Inc. | Inverting braided aneurysm treatment system and method |
US11497504B2 (en) | 2019-05-21 | 2022-11-15 | DePuy Synthes Products, Inc. | Aneurysm treatment with pushable implanted braid |
US11583282B2 (en) | 2019-05-21 | 2023-02-21 | DePuy Synthes Products, Inc. | Layered braided aneurysm treatment device |
US11607226B2 (en) | 2019-05-21 | 2023-03-21 | DePuy Synthes Products, Inc. | Layered braided aneurysm treatment device with corrugations |
US11679458B2 (en) | 2019-11-04 | 2023-06-20 | Covidien Lp | Devices, systems, and methods for treating aneurysms |
US11685007B2 (en) | 2019-11-04 | 2023-06-27 | Covidien Lp | Devices, systems, and methods for treatment of intracranial aneurysms |
US11717924B2 (en) | 2019-11-04 | 2023-08-08 | Covidien Lp | Devices, systems, and methods for treatment of intracranial aneurysms |
US11633818B2 (en) | 2019-11-04 | 2023-04-25 | Covidien Lp | Devices, systems, and methods for treatment of intracranial aneurysms |
US11602350B2 (en) | 2019-12-05 | 2023-03-14 | DePuy Synthes Products, Inc. | Intrasaccular inverting braid with highly flexible fill material |
US11457926B2 (en) | 2019-12-18 | 2022-10-04 | DePuy Synthes Products, Inc. | Implant having an intrasaccular section and intravascular section |
Also Published As
Publication number | Publication date |
---|---|
EP1824396A1 (en) | 2007-08-29 |
WO2006055182A1 (en) | 2006-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060106421A1 (en) | Expansible neck bridge | |
US6036720A (en) | Sheet metal aneurysm neck bridge | |
US7645292B2 (en) | Vaso-occlusive devices with in-situ stiffening elements | |
JP4057776B2 (en) | Removable aneurysm neck bridge (II) | |
US11504816B2 (en) | Systems and methods for treating aneurysms | |
EP1109499B1 (en) | Detachable aneurysm neck closure patch | |
US6139564A (en) | Minimally occlusive flow disruptor stent for bridging aneurysm necks | |
CA2481224C (en) | Devices for retaining vaso-occlussive devices within an aneurysm | |
EP2008596B1 (en) | Embolic device | |
EP1003422B1 (en) | Detachable aneurysm neck bridge | |
US20050149109A1 (en) | Expanding filler coil | |
US20040098023A1 (en) | Embolic device made of nanofibers | |
EP2005979A2 (en) | Multiple point detacher system | |
US20170245865A1 (en) | Intralumenal Occlusion Devices Having Improved Properties | |
WO2004091712A2 (en) | Bioactive components for incorporation with vaso-occlusive members | |
WO2006102329A1 (en) | Multi-layer coaxial vaso-occlusive device | |
US9504474B2 (en) | Vaso-occlusive devices with in-situ stiffening | |
US20180221030A1 (en) | Devices and Methods for Treatment of Endovascular and Non-Endovascular Defects in Humans Using Tandem Embolization Devices | |
US20050090856A1 (en) | Vasco-occlusive devices with bioactive elements | |
EP1543850B1 (en) | Activatable bioactive implantable vascular occlusion device | |
EP1543783B1 (en) | Activable bioactive implantable medical device. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEOH, CLIFFORD;REEL/FRAME:016077/0704 Effective date: 20041116 |
|
AS | Assignment |
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018505/0868 Effective date: 20050101 Owner name: BOSTON SCIENTIFIC SCIMED, INC.,MINNESOTA Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018505/0868 Effective date: 20050101 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: STRYKER MEDTECH LIMITED, MALTA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER NV OPERATIONS LIMITED;REEL/FRAME:037153/0034 Effective date: 20151013 Owner name: STRYKER EUROPEAN HOLDINGS I, LLC, MICHIGAN Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER MEDTECH LIMITED;REEL/FRAME:037153/0241 Effective date: 20151013 |
|
AS | Assignment |
Owner name: STRYKER NV OPERATIONS LIMITED, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOSTON SCIENTIFIC LIMITED;REEL/FRAME:037156/0336 Effective date: 20110103 Owner name: STRYKER CORPORATION, MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOSTON SCIENTIFIC LIMITED;REEL/FRAME:037156/0336 Effective date: 20110103 |
|
AS | Assignment |
Owner name: STRYKER EUROPEAN HOLDINGS I, LLC, MICHIGAN Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT LISTED SERIAL NOS. 09/905,670 AND 07/092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0241. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT EFFECTIVE DATE 9/29/2014;ASSIGNOR:STRYKER MEDTECH LIMITED;REEL/FRAME:038043/0011 Effective date: 20151013 Owner name: STRYKER MEDTECH LIMITED, MALTA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL # 09/905,670 AND 07/092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0034. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER NV OPERATIONS LIMITED;REEL/FRAME:038039/0001 Effective date: 20151013 |
|
AS | Assignment |
Owner name: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC, MICHIGAN Free format text: CHANGE OF NAME;ASSIGNOR:STRYKER EUROPEAN HOLDINGS III, LLC;REEL/FRAME:052860/0716 Effective date: 20190226 Owner name: STRYKER EUROPEAN HOLDINGS III, LLC, DELAWARE Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER EUROPEAN HOLDINGS I, LLC;REEL/FRAME:052861/0001 Effective date: 20200519 |